Hepatocellular carcinoma is one of the most prevalent malignant diseases and causes a third of cancer-related death. The consequences of altered calcium homeostasis in cancer cells may contribute to tumor progression. Regucalcin plays an inhibitory role in calcium signaling linked to transcription regulation. Regucalcin gene expression is downregulated in the tumor tissues of liver cancer patients, suggesting an involvement as a suppressor in hepatocarcinogenesis. We investigated whether Bay K 8644, an agonist of the L-type Ca2+ channel, promotes the growth of human liver cancer and if the effect of Bay K 8644 is suppressed by overexpressed regucalcin using the HepG2 cell model. The colony formation and growth of HepG2 cells were promoted by culturing with Bay K 8644 (0.1–10 nM). This effect was suppressed by inhibitors of signaling processes linked to cell proliferation, including PD98059 and wortmannin. Death of HepG2 cells was stimulated by Bay K 8644 with higher concentrations (25 and 100 nM). The effects of Bay K 8644 on cell growth and death were abolished by verapamil, an antagonist of calcium channel. Mechanistically, culturing with Bay K 8644 increased levels of mitogen-activated protein kinase (MAPK) and phospho-MAPK. Notably, overexpressed regucalcin suppressed Bay K 8644-promoted growth and death of HepG2 cells. Furthermore, overexpressed regucalcin prevented growth and increased death induced by thapsigargin, which induces the release of intracellular stored calcium. Thus, higher regucalcin expression suppresses calcium signaling linked to the growth of liver cancer cells, providing a novel strategy in treatment of hepatocellular carcinoma with delivery of the regucalcin gene.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
The datasets used during the present study are available from the corresponding author upon reasonable request.
Sayiner M, Golabl P, Younossi Z (2019) Disease burden of hepatocellular carcinoma: a global perspective. Dig Dis Sci 64:910–917
Mak LY, Cruz-Ramon V, Chinchilla-Lopez P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Mendez-Sanchez N, Yuen MF, Hwang JP (2018) Global epidemiology, ptrevention, and management of hepatocellularcarcinoma. Am Soc Clin Oncol Educ Book 38:262–279
El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365:1118–1127
Dragani TA (2010) Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 52:252–257
Cha MY, Kim CM, Park YM, Ryu WS (2004) Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. Hepatology 39:1683–1693
Shin JW, Chung Y-H (2013) Molecular targeted therapy for hepatocellular carcinoma: current and future. World J Gatroenterol 19:6144–6155
Meena AS, Sharma A, Kumari R, Mohammad N, Singh VS, Bhat MK (2013) Inherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involved. PLoS ONE 8:e61524. https://doi.org/10.1371/journal.pone.0061524
Mohammad N, Singh SV, Malvi P, Chaube B, Athavale D, Vanuopadath M, Nair SS, Nair B, Bhat MK (2015) Strategy to enhance efficancy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: involvement of p53 and Fas receptor ligand complex. Sci Rep 5:11853. https://doi.org/10.1038/srep11853
Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129–3140
Callegari E, Elamin BK, Sabbioni S, Gramantieri NM (2013) Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targ Ther 6:1167–1178
Monteith GR, Davis FM, Roberts-Thompson SJ (2012) Calcium channels and pumps in cancer: changes and consequences. J Biol Chem 287:31666–33167
Tennakoon S, Aggarwal A, Kallay E (2016) The calcium-sensing receptor and the Hallmarks of cancer. Biochim Biophys Acta 1863:1398–1407
Varghese E, Samuel SM, Sadiq Z, Kubatka P, Liskova A, Benacka J, Pazinka P, Kruzliak P, Busselberg P (2019) Anti-cancer agents in proliferation and cell death: the calcium connection. Int J Mol Sci 20:3017. https://doi.org/10.3390/ijms20123017
Resende RR, Andrade LM, Oliveira AG, Guimaraes ES, Guatimosim S, Leite MF (2013) Nucleoplasmic calcium signaling and cell proliferation: calcium signaling in the nucleus. Cell Commun Signal 11:14. https://doi.org/10.3390/ijms20123017
Yamaguchi M, Yamamoto T (1978) Purification of calcium binding substance from soluble fraction of normal rat liver. Chem Pharm Bull (Tokyo) 26:1915–1918
Shimokawa N, Yamaguchi M (1993) Molecular cloning and sequencing of the cDNA coding for a calcium-binding protein regucalcin from rat liver. FEBS Lett 327:251–255
Shimokawa N, Matsuda Y, Yamaguchi M (1995) Genomic cloning and chromosomal assignment of rat regucalcin gene. Mol Cell Biochem 151:157–163
Yamaguchi M (2005) Role of regucalcin in maintaining cell homeostasis and function. Int J Mol Med 15:372–389
Yamaguchi M (2011) Regucalcin and cell regulation: role as a suppressor in cell signaling. Mol Cell Biochem 353:101–137
Yamaguchi M (2011) The transcriptional regulation of regucalcin gene expression. Mol Cell Biochem 346:147–171
Yamaguchi M (2013) Role of regucalcin in cell nuclear regulation: involvement as a transcription factor. Cell Tissue Res 354:331–341
Yamaguchi M (2013) Suppressive role of regucalcin in liver cell proliferation: Involvement in carcinogenesis. Cell Prolif 46:243–253
Yamaguchi M (2013) The anti-apoptotic effect of regucalcin is mediated through multisignaling pathways. Apoptosis 18:1145–1153
Yamaguchi M (2015) Involvement of regucalcin as a suppressor protein in carcinogenesis. Insight into the gene therapy. J Cancer Res Clin Oncol 141:1333–1341
Yamaguchi M, Osuka S, Weitzmann MN, El-Rayes BF, Shoji S, Murata T (2016) Prolonged survival in pancreatic cancer patients with increased regucalcin gene expression: overexpression of regucalcin suppresses the proliferation in human pancreatic cancer MIA PaCa-2 cells in vitro. Int J Oncol 48:1955–1964
Yamaguchi M, Osuka S, Weitzmann MN, Shoji S, Murata T (2016) Increased regucalcin gene expression extends survival in breast cancer patients: overexpression of regucalcin suppresses the proliferation and metastatic bone activity in MDA-MB-231 human breast cancer cells in vitro. Int J Oncol 49:812–822
Yamaguchi M, Osuka S, Weitzmann MN, Shoji S, Murata T (2016) Prolonged survival in hepatocarcinoma patients with increased regucalcin gene expression: HepG2 cell proliferation is suppressed by overexpression of regucalcin in vitro. Int J Oncol 49:1686–1694
Yamaguchi M, Osuka S, Shoji S, Weitzmann MN, Murata T (2017) Survival of lung cancer patients is prolonged with higher regucalcin gene expression: suppressed proliferation of lung adenocarcinoma A549 cells in vitro. Mol Cell Biochem 430:37–46
Yamaguchi M, Osuka S, Murata T (2018) Prolonged survival of colorectal cancer patients is associated with higher regucalcin gene expression: overexpressed regucalcin suppresses growth of human colorectal carcinoma cells in vitro. Int J Oncol 53:1313–1322
Yamaguchi M, Osuka S, Hankinson O, Murata T (2019) Prolonged survival of renal cancer patients is concomitant with a higher regucalcin gene expression in the tumor tissues: overexpression of regucalcin depresses the growth of human renal cell carcinoma cells in vitro. Int J Oncol 54:188–198
Li X, Huang Y, Guo S, Xie M, Bin X, Shi M, Chen A, Chen S, Wu F, Hu Q, Zhou S (2019) Exogenous regucalcin negatively regulates the progression of cervical adenocarcinoma. Oncol Lett 18:609–616
Yamaguchi M, Murata T (2020) Overexpression of regucalcin supresses the growth of human osteosarcoma cells in vitro: repressive effect of extracellular regucalcin. Cancer Invest 38:37–51
Nitschkowski D, Marwitz S, Kotanidou SA, Reck M, Kugler C, Rabe KF, Ammerpohi O, Goldmann T (2019) Live and let die: epigenetic modifications of survivin and regucalcin in non-small cell lung cancer tissues contribute to malignancy. Clin Epigenet 11:157. https://doi.org/10.1186/s13148-019-0770-6
Yamaguchi M (2000) Role of regucalcin in calcium signaling. Life Sci 66:1769–1780
Panner A, Wurster RD (2006) T-type calcium channels and tumor proliferation. Cell Calcium 40:253–259
Monge L, Silvestre RA, Miralles P, Peiro E, Villanueva ML, Marco J (1988) In vitro effects of Bay K 8644, a dihydropyridine derivative with hypoglycaemic properties, on hepatic glucose production and pancreatic hormone secretion. Biochem Pharmacol 37:2933–2937
Knowles BB, Howe CC, Aden DP (1980) Human hepatocellular carcinoma cell lines secrete the major plasma protein and hepatitis B surface antigen. Science 209:497–499
Ao L, Guo Y, Song X, Guan Q, Zheng W, Zhang J, Huang H, Guo Z, Wang X (2017) Evaluating hepatocellular carcinoma cell lines for tumour samples using within-sample relative expression orderings of genes. Liver Int 37:1688–1696
Misawa H, Inagaki S, Yamaguchi M (2002) Suppression of cell proliferation and deoxyribonucleic acid synthesis in cloned rat hepatoma H4-II-E cells overexpressing regucalcin. J Cell Biochem 84:143–149
Fang Z, Tang Y, Fang J, Zhou Z, Xing Z, Guo Z, Guo X, Wang W, Jiao W, Xu Z, Liu Z (2013) Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. PLoS ONE 17(8):e62823
Yamaguchi M, Daimon Y (2005) Overexpression of regucalcin suppresses cell proliferation in cloned rat hepatoma H4-II-E cells: Involvement of intracellular signaling factors and cell cycle-related genes. J Cell Biochem 95:1169–1177
Izumi T, Yamaguchi M (2004) Overexpression of regucalcin suppresses cell death in cloned rat hepatoma H4-II-E cells induced by tumor necrosis factor-α or thapsigargin. J Cell Biochem 92:296–306
Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita E (1986) Staurosporine, a potent inhibitor of phospholipid/Ca2+ dependent protein kinase. Biochem Biophys Res Commun 135:397–402
Nakagawa T, Sawada N, Yamaguchi M (2005) Overexpression of regucalcin suppresses cell proliferation of cloned normal rat kidney proximal tubular epithelial NRK52E cells. Int J Mol Med 16:637–643
Peleck SL, Charest DL, Mordret GP, Siow YL, Palaty C, Campbell D, Chaslton L, Samiei M, Sanghera JS (1993) Networking with mitogen-activated protein kinases. Mol Cell Biochem 127:157–169
Serrano-Nascimento C, da Silva TS, Nicola JP, Nachbar RT, Masini-Repiso AM, Nunes MT (2014) The acute inhibitory effect of iodide excess on sodium/iodide symporter expression and activity involves the PI3K/Akt signaling pathway. Endocrinology 155:1145–1156
Vohra J (1982) Verapamil in cardiac arrhythmias: an overview. Clin Exp Pharmacol Physiol Suppl 6:129–134
Kaneko Y, Tsukamoto A (1994) Thapsigargin-induced persistent intracellular calcium pool depletion and apoptosis in human hepatoma cells. Cancer Lett 79:147–155
Rosado JA, Rosenzweig I, Harding S, Sage SO (2001) Tumor necrosis factor-α inhibits store-mediated Ca2+ entry in the human hepatocellular carcinoma cell line. Am J Physiol Cell Physiol 280:C1636–C1644
Ali ES, Rychkov GY, Barritt GJ (2019) Deranged hepatocyte intracellular Ca2+ homeostasis and the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma. Cell Calcium 82:102057. https://doi.org/10.1016/j.ceca.2019.102057
Yamaguchi M, Sakurai T (1991) Inhibitory effect of calcium-binding protein regucalcin on Ca2+-activated DNA fragmentation in rat liver nuclei. FEBS Lett 279:281–284
Tsurusaki Y, Yamaguchi M (2004) Role of regucalcin in liver nuclear function: Binding of regucalcin to nuclear protein or DNA and modulation of tumor-related gene expression. Int J Mol Med 14:277–281
Mori S, Yamaguchi M (1990) Hepatic calcium-binding protein regucalcin decreases Ca2+/calmodulin-dependent protein kinase activity in rat liver cytosol. Chem Pharm Bull (Tokyo) 38:2216–2218
Yamaguchi M, Mori S (1990) Inhibitory effect of calcium-binding protein regucalcin on protein kinase C activity in rat liver cytosol. Biochem Med Metab Biol 43:140–146
Murata T, Yamaguchi M (1997) Molecular cloning of the cDNA coding for regucalcin and its mRNA expression in mouse liver: The expression is stimulated by calcium administration. Mol Cell Biochem 173:127–133
Murata T, Yamaguchi M (1998) Ca2+ administration stimulates the binding of AP-1 factor to the 5’-flanking region of the rat gene for the Ca2+-binding protein regucalcin. Biochem J 329:157–163
Takahashi H, Yamaguchi M (1999) Role of regucalcin as an activator of Ca2+-ATPase activity in rat liver microsomes. J Cell Biochem 74:663–669
Takahashi H, Yamaguchi M (2000) Stimulatory effect of regucalcin on ATP-dependent Ca2+ uptake activity in rat liver mitochondria. J Cell Biochem 78:121–130
Yamaguchi M, Mori S, Kato S (1988) Calcium-binding protein regucalcin is an activator (Ca2+–Mg2+)-adenosine triphosphatase in the plasma membranes of rat liver. Chem Pharm Bull (Tokyo) 36:3532–3539
This study was supported in part by funds provided by the University of Hawaii Cancer Center and the B.H. and Alice C. Beams Endowed Professorship in Cancer Research from the John A. Burns School of Medicine (J.W.R.), and the Foundation for Biomedical Research on Regucalcin, Japan (M.Y.).
Conflict of interest
All authors declare that they have no conflicts of interest.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors. All experimental protocols used databases or cell culture in vitro.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Yamaguchi, M., Murata, T. & Ramos, J.W. The calcium channel agonist Bay K 8644 promotes the growth of human liver cancer HepG2 cells in vitro: suppression with overexpressed regucalcin. Mol Cell Biochem (2020). https://doi.org/10.1007/s11010-020-03795-7
- Bay K 8644
- Cell proliferation
- Liver cancer
- HepG2 cells
- Calcium signaling